Log In

Forgot Password?

OR

Not a member? Continue as a nonmember.

Become a Member

By becoming a member of the AAN, you can receive exclusive information to help you at every stage of your career. Benefits include:

Join Now See All Benefits

Loading... please wait

Abstract Details

Real-world Reductions in Migraine and Headache Days for Patients With Chronic and Episodic Migraine Initiating Fremanezumab in the US
Headache
Headache Posters (7:00 AM-5:00 PM)
120

Fremanezumab, a fully-humanized monoclonal antibody (IgG2Δa) that selectively targets the calcitonin gene-related peptide (CGRP), has been approved for preventive migraine treatment in adults. Real-world effectiveness data for fremanezumab in reducing MMD and MHD are needed to understand the treatment’s full clinical benefit.

This retrospective, panel-based online physician chart review aimed to assess the effectiveness of fremanezumab in reducing monthly migraine days (MMD) and monthly headache days (MHDs) in adult chronic migraine (CM) and episodic migraine (EM) patients over up to 6 months.

This panel-based chart review used electronic case report forms. Patient inclusion criteria were a physician diagnosis of CM or EM; fremanezumab treatment initiation at ≥18 years of age after FDA approval (treatment initiation, October 2, 2018–July 17, 2020); ≥1 dose of fremanezumab treatment; and ≥2 MMD assessments (1 within 30 days before treatment initiation and ≥1 after initiation).

This study included data from 421 clinicians and 1,003 patients (CM, n=587; EM, n=416). Mean age at fremanezumab initiation was 39.7 years; most patients were female (76%). Mean baseline MMDs were 12.7 overall (CM, 14.7; EM, 10.0), and MHDs were 14.0 overall (CM, 16.4; EM, 10.7). Mean (percent) reductions from baseline in MMDs and MHDs, respectively, were –4.6(36.2%) and –4.7(33.6%) in the overall population, –5.5(37.4%) and –5.1(31.1%) in CM patients, and –3.4(34.0%) and –4.1(38.3%) in EM patients at Month 1; –6.7(52.8%) and –6.8(48.6%) in the overall population, –7.9(53.7%) and –8.0(48.8%) in CM patients, and –4.7(47.0%) and –4.9(45.8%) in EM patients at Month 3; and –9.2(72.4%) and –9.8(70.0%) in the overall population, –10.1(68.7%) and –10.8(65.9%) in CM patients, and –7.7(77.0%) and –8.0(74.8%) in EM patients at Month 6.

In this real-world study, fremanezumab treatment resulted in clinically meaningful reductions in MMDs and MHDs sustained over up to 6 months for both CM and EM patients.

Authors/Disclosures
Joshua M. Cohen, MD
PRESENTER
No disclosure on file
Stephen F. Thompson Stephen Thompson has received personal compensation for serving as an employee of Teva Pharmaceuticals.
Oscar Patterson-Lomba Oscar Patterson-Lomba has nothing to disclose.
Maurice Driessen (Teva) Maurice Driessen has received personal compensation for serving as an employee of Teva Pharmaceuticals.
Michael Seminerio Michael Seminerio has received personal compensation for serving as an employee of AbbVie.
Karen Carr (Teva) Karen Carr has received stock or an ownership interest from Teva Pharmaceuticals. An immediate family member of Karen Carr has received stock or an ownership interest from Genentech.
Fan Mu, PhD Fan Mu, PhD has nothing to disclose.